Iljovska, Marina

Preferred name

Iljovska, Marina

Official Name

Iljovska, Marina

Main Affiliation

marina.iljoska@medf.ukim.edu.mk

Now showing 1 - 4 of 4

Some of the metrics are blocked by your
consent settings
Breast cancer tumor characteristics and metastatic bone scintigraphy findings
(Department of Anaesthesia and Reanimation, Faculty of Medicine, Ss. Cyril and Methodius University in Skopje, R.N. Macedonia, 2023-10-09)
;
;
Lazareva E
;
;
Objectives: Bone scintigraphy (BS) is the gold standard for screening and initial diagnosis of bone metastases (BMs) in breast cancer (BC). The aim of this study was to analyze the correlation between multiple BMs diagnosed on BS with the tumor characteristics and molecular subtypes of the tumor in BC patients. Materials and Methods: We performed a retrospective, observational study of 66 BC patients (mean age 52.52±10.64 years) with multiple BMs confirmed on the first diagnostic BS, in the period 2013-2018. Data regarding the initial disease stage, tumor histological type, grade and molecular subtype were evaluated for correlation with BMs. Results: Sixteen patients (24%) presented with BMs at the time of BC. The metastasis-free period in the restaging group was 7.38±4.01 years and the same was significantly associated with the disease TNM stage (rs =-0.385; P=0.011). Ductal BC was more frequently associated with BMs than the lobular type (65% vs. 14%, respectively). ER+ were 86% of the cases, followed by PgR+ (74%) and HER2+ (35%) of the cases. A significant correlation was found between the HR+ status of BC patients and the presence of multiple BMs (P=0.021). BMs were mainly detected in the spine (predominantly the thoracic segment), the ribs and the pelvis (P= 0.013). Conclusion: Higher initial TNM stage reduces BMs free interval. HR positive status seems to be a significant predictor of BMs in BC.
Some of the metrics are blocked by your
consent settings
The highest frequency of BRCA1 c.3700_3704del detected among Albanians from Kosovo
(Greater Poland Cancer Centre, Poland, 2022)
Kostovska Maleva, Ivana
;
Jakovchevska, Simona
;
Özdemir, Milena Jakimovska
;
Kiprijanovska, Sanja
;
Kubelka-Sabit, Katerina
Background: The spectrum of BRCA1 and BRCA2 mutations varies among populations; however, some mutations may be frequent in particular ethnic groups due to the “founder” effect. The c.3700_3704del mutation was previously described as a recurrent BRCA1 variant in Eastern European countries. This study aimed to investigate the frequency of c.3700_3704del BRCA1 mutation in Albanian breast and ovarian cancer patients from North Macedonia and Kosovo. Materials and methods: A total of 327 patients with invasive breast and/or ovarian cancer (111 Albanian women from North Macedonia and 216 from Kosovo) were screened for 13 recurrent BRCA1/2 mutations. Targeted NGS with a panel of 94 cancer-associated genes including BRCA1 and BRCA2 was performed in a selected group of 118 patients. Results: We have identified 21 BRCA1/2 pathogenic variants, 17 (14 BRCA1 and 3 BRCA2) in patients from Kosovo (7.9%) and 4 (1 BRCA1 and 3 BRCA2) in patients from North Macedonia (3.6%). All BRCA1/2 mutations were found in one patient each, except for c.3700_3704del BRCA1 mutation which was observed in 14 unrelated families, all except one originating from Kosovo. The c.3700_3704del mutation accounts for 93% of BRCA1 mutation positive cases and is present with a frequency of 6% among breast cancer patients from Kosovo. Conclusions: This is the first report of BRCA1/2 mutations among breast and ovarian cancer patients from Kosovo. The finding that BRCA1 c.3700_3704del represents a founder mutation in Kosovo with the highest worldwide reported frequency supports the implementation of fast and low-cost screening protocol, regardless of the family history and even a pilot population-based screening in at-risk population.
Some of the metrics are blocked by your
consent settings
Real-world data of cardiotoxicity during long-term therapy with trastuzumab in human epidermal growth factor receptor-2-positive metastatic breast cancer
(National Library of Serbia, 2022-12-16)
;
Lazareva, Emilija
;
;
;
Introduction/Objective. This study aims to investigate the cardiotoxicity of long-term therapy with trastuzumab in patients with HER2 positive metastatic breast cancer. Methods. A total of 48 patients with metastatic HER2 positive breast cancer were analyzed. The patients received long-term trastuzumab (time of application was longer than 20 months). The analyzed characteristics of the patients were: age, initial stage of the disease, application of anti-HER2 therapy and anthracyclines in the adjuvant setting, the number and type of applied systemic therapies concomitant with trastuzumab in the metastatic setting. Cardiac toxicity was assessed using left ventricular ejection fraction (LVEF) values at three time points: at the beginning, in the middle, and at the end of treatment period for each patient separately. Results. In 17 (35.4%) patients the trastuzumab treatment was temporary discontinued. The average time of trastuzumab therapy interval was 52.2 ? 23.5 months. The mean LVEF values were 66.73 ? 7.02%, 64.62 ? 5.7% and 63.44 ? 6.1%, respectively. The mean values of LVEF differed significantly in the observed three time points (F=4.9 p=0.009). Post hoc pairwise comparison, using Bonferonni correction, confirmed significantly lower mean LVEF values at the end point (at the end of treatment) compared with the mean LVEF values at the beginning of anti-HER2 treatment (p = 0.019), but within the reference range of LVEF ?50%. Conclusion. The data confirm good safety profile of long-term trastuzumab therapy in HER2 positive metastatic breast cancer patients considering cardiotoxicity.
Some of the metrics are blocked by your
consent settings
Adjuvant chemotherapy plus concurrent chemoradiotherapy (CCRT) in advanced gastric adenocarcinoma treatment as standard of care
(2020)
;
;
Lazarova, Emilija
;
;
Berat, Meri
Introduction. Despite a worldwide decline in incidence based on GLOBOCAN 2018 data, stomach cancer is the 5th most common neoplasm and the 3rd most deadly cancer. In 90% of cases, its histology is adenocarcinoma, either of the intestinal type or of diffuse. Helicobacter pylori infection, smoking, salt and nitrate-rich foods are the most important factors of risk. The interactions between dietary factors, environmental factors and the development of gastric cancer are well described with clearly identified dietary exposures strongly associated with gastric cancer induction and prevention. Postoperative fluoropyrimidine-based CCRT and chemotherapy is standard adjuvant treatment of resected gastric adenocarcinoma. Materials and methods. Patients with subtotal gastrectomy and D1 lymph node dissection were treated with 2 cycles of Capecitabine (DD 2500 mg/m2 po bid/21day cycle) followed by chemoradiotherapy and another of 2 cycles chemotherapy with Capecitabine (DD 2500 mg/m2 po bid/21d cycle). CT simulation with oral contrast application was performed followed by delineation of target volumes and organs at risk according to CRITICS protocol. 3D conformal postoperative chemoirradiation was delivered with standard fractionation (TTD 50.4 Gy/1.8 Gy) with concurrent application of Capecitabine 1650mg/m2/bid/d1-5. Adjuvant treatment was delivered in postoperative period of 6 months. Results. Adjuvant chemotherapy and chemoradiotherapy prolongs disease free survival (DFS) and improves quality of life. CT-based 3D conformal treatment planning and delivery of postoperative chemoirradiation is minimum standard of care of gastric cancer treatment. Conclusion. Multidisciplinary decision making team approach is preferred. Primary treatment option for patients with potentially resectable locoregional gastric tumors is surgery. The guidelines have included postoperative chemo/chemoradiotherapy treatment depending of tumor stage, nodal status, extent of lymph node dissection and other risk factors (differentiation, lymphovascular invasion, neural invasion, surgical margins). Adjuvant chemotherapy and chemoradiotherapy prolongs disease free survival (DFS) and improves quality of life. Keywords: Gastric cancer, chemoirradiation, CCRT, DFS, 3D conformal, postoperative

Iljovska, Marina

Filters

Settings

Sort By

Results per page